HD (6,547€-95%CI: 5,727€-7,366€-) was significantly higher (pϽ0.001) than TX (5,079€-95%CI:4,127€-6,030€-) or APD (4,359€-95%CI:3,064€-5,655€-) but not CAPD (5,785€-95%CI:4,302€-7,269€-). PPYLtc was higher in HD than in TX, APD or CAPD in all the provided scenarios. CONCLUSIONS: APD is the alternative with the lowest impact on indirect costs due to morbidity. Besides, TX recipients also have higher rates of employment than HD and require less disability benefits.
PUK8

4-YEAR INCIDENCE AND COSTS OF HOSPITALIZED COMPLICATIONS WITHIN KIDNEY TRANSPLANT PATIENTS IN FRANCE
Vainchtock A 1 , Fernandes J 2 , Cotté FE 3 , Chaize G 4 , Gaudin AF 5 1 HEVA, LYON, France, Montpellier, France, 3 Bristol-Myers Squibb, Rueil-Malmaison, France, 4 HEVA, Lyon, France, 5 Bristol-Myers-Squibb, Rueil Malmaison, France OBJECTIVES: Complications are common following kidney transplantation. The French Hospital National Database (PMSI) allows patients follow-up through their hospitalization reports. This study assessed 4-year incidences of complications after kidney transplantation and estimated their economic impact, in particular renal complications. METHODS: From the years 2006-2010, hospitalization data for all patients with kidney transplantation in year 2006 were extracted. Patients' hospital stays were followed during a period of 4 years. Major hospitalizations of interests were pooled in renal, cardiovascular and infectious complications. Renal complications were detailed in graft loss, acute renal insufficiency (ARI), acute rejection (AR), recurrence of initial nephropathy (RIN), chirurgical complication and, others. Incremental costs were estimated by subtracting transplantation-year mean cost of patients without any renal complications to the one of those with renal complications the same year. Mean annual costs of patients with graft loss were assessed separately for each year. Costs were calculated according to the 2010 National Hospital Tariff and National Scale. RESULTS: A total of 2392 patients with kidney transplantation in 2006 were identified. A total of 61.5% were males and mean age was 45.0(Ϯ14.9) years old. 4-year cumulative incidences of renal, cardiovascular and infectious complications were 54.8% (nϭ1,311), 20.8% (nϭ498) and 19.8% (nϭ474). Incidences of ARI, AR, RNI, chirurgical complication and, others renal complications were 24.5%, 21.1%, 4.1%, 3.1% and 22.4%, respectively. Compared to other patients without any renal complication (First-year mean costs: €25,170; Q1:€17,341-Q3:€27,649), the corresponding incremental costs for renal complications were €7,046, €10,376, €10,238, €7,874 and, €5,668. During the 4-year period, graft loss occurred in 4.4% patients. Annual mean costs of graft loss for the first, second, third and fourth years were €32,159 (Q1:€11 723-Q3:€41,890) (nϭ105), €19,085 (nϭ64), €25,269 (nϭ52) and, €20,780 (nϭ41), respectively. CONCLUSIONS: After transplantation, short-term renal complications are frequent and expensive. Intensive interventions on renal preservation and graft loss prevention are needed.
PUK9 DIRECT AND INDIRECT COST OF URGE URINARY INCONTINENCE WITH AND WITHOUT PHARMACOTHERAPY
Goren A 1 , Zou KH 2 , Gupta S 3 , Chen CI 2 1 Kantar Health, New York, NY, USA, 2 Pfizer, Inc., New York, NY, USA, 3 Kantar Health, Princeton, NJ, USA OBJECTIVES: To evaluate the impact of treating urge urinary incontinence (UUI) on health care resource utilization, productivity, activity impairment, and associated costs. METHODS: The study used data (Nϭ75,000) from the 2011 National Health and Wellness Survey, a self-administered, Internet-based questionnaire of a nationwide sample of adults (age Ն18). Respondents with UUI or MUI were identified via 3 Incontinence Questions. Respondents with stress urinary incontinence only, prostate cancer, or (medication for) benign prostatic hyperplasia, were excluded. UUI/MUI respondents were categorized as using prescription medication (Rx users) for overactive bladder (OAB) and non-Rx users (who never used Rx and whose condition reportedly interfered with life activities or was difficult to manage). Outcome measures included health care utilization (type/number of resources used within the past 6 months) and Work Productivity and Activity Impairment questionnaire-based scores. Direct and indirect costs were estimated using 2010 labor and 2008 medical expenditure data sources. Generalized linear models predicted resource use and productivity as a function of treatment status, adjusting for covariates (e.g., sociodemographics, BMI, OAB severity, UUI vs. MUI, and comorbid status) that may also predict impairment. RESULTS: Among 1,190 UUI/MUI respondents, 481 were defined as Rx and 709 as non-Rx users. Rx (vs. non-Rx) users were more likely to be female (80.7% vs. 70.0%), older (meanϭ62.7 vs. 53.1), non-Hispanic White (82.3% vs. 69.7%), college educated, health-insured (94.6% vs. 81.7%), unemployed/retired (72.6% vs. 57.7%), and reporting more moderate-to-severe OAB (70.9% vs. 52.6%; all pϽ0.05). Adjusting for covariates, Rx (vs. non-Rx) users had lower activity impairment (41.1% vs. 46.8%), more provider visits (7.42 vs. 5.60) and costs ($18,175 vs. $13,679) , and higher total direct costs ($27,291 vs. $21,493), all pϽ0.01. CONCLUSIONS: UUI patients using, vs. never using, prescription medication reported lower activity impairment but higher direct costs. The findings may inform the degree to which UUI pharmacotherapy affects health outcomes.
PUK10 COMPARATIVE COST-ANALYSIS OF SIX ANTICHOLINERGICS FOR THE TREATMENT OF OVERACTIVE BLADDER AND INCONTINENCE IN GERMANY
Mayrhofer T 1 , Grabe K 2 , Felder S 3 1 University of Duisburg-Essen, Essen, Germany, 2 Astellas Pharma GmbH, Munich, Germany, 3
University of Basel, Basel, Switzerland
OBJECTIVES: Comparing the costs of Solifenacin, Oxybutynin, Trospium chloride, Tolterodine, Propiverine, and Darifenacine for the treatment of overactive bladder (OAB) and incontinence in Germany. DATA AND METHODS: The cost-study is based on a unique sickness fund dataset of 2.9 million insured persons which included pharmaceutical, outpatient, inpatient, medical aids as well as remedies data in 2009. 25,896 persons received anticholinergics and were classified as OAB patients. 4,152 of these patients also suffered from incontinence. Multiple linear regression models were performed to control for age and gender effects. Furthermore, a general approach (all costs were included) as well as a specific approach (only costs associated with OAB were considered) were used. RESULTS: OAB patients caused additional costs of €2,492 using the general and €782 using the specific approach compared to Non-OAB patients. Patients treated with Propiverine (€1,854) had the lowest additional costs under the general approach and patients treated with Darifenacine (€3,230) the highest. In the specific approach, patients treated with Propiverine (€691) had the lowest additional costs and patients treated with Tolterodine (€1,124) the highest. In the special case of incontinence, patients treated with Solifenacin have shown, by far, the lowest additional costs using either approach (€3,216; €1,320). These results are mainly driven by the lower costs A456 of aids, especially due to the lower pad usage. Patients treated with Trospium chloride (€5,409) exhibited the highest costs using the general approach and patients treated with Tolterodine (€2,198) incurred the highest costs using the specific approach. All results were highly significant (pϽ0.01). CONCLUSIONS: This study compares the costs of six anticholinergics for the treatment of OAB and incontinence in Germany. OAB patients treated with Propiverine and incontinent patients treated with Solifenacin have shown the lowest additional costs. For both patient groups Tolterodine is associated with the highest additional cost of treatment. We identified following health states: Graft survive, Acute graft rejection (AR), Post-rejection, Dialysis, Re-transplantation. Patients may Die from each state. Drug acquisition cost of tacrolimus OD was 10% higher compared to BD, other costs of AR (1,799€), dialysis (33,675€) and transplantation (16,631€) were derived by an expert panel and local pricing lists. The costs and outcomes were discounted by 3% rate. We performed One-Way-Sensitivity (OWSA) and Probabilistic-Sensitivity (PSA) analyses using 20% deviation from base-case. RESULTS: The model predictability, in term of patients' survival within 15 year horizon, was validated according to mortality data in several kidney transplant patients' registries. The deterministic results in 15 year horizon showed that tacrolimus OD generated costs of 67,457€ (10.714 LYG) and tacrolimus BD 68,316€ (10.581 LYG), tacrolimus BD revealed incremental costs of 859€ and -0.133 LYG. PSA showed 96.7% probability of tacrolimus OD being dominant and 3.3% below defined threshold of 1 GDP/ capita in the Czech Republic. CONCLUSIONS: Tacrolimus OD is dominant intervention (lower costs and simultaneously higher outcomes) despite 10% higher acquisition costs compared to tacrolimus BD. OWSA showed that the results were the most sensitive on tacrolimus acquisition cost, compliance rate and cost of dialysis. OBJECTIVES: Standard of care and use of immunosuppressive drugs in renal transplant recipients have changed in recent years. We provide an updated pharmacoeconomic model which uses state of the art methodological standards in pharmacoeconomics based upon current evidence. To our knowledge this is the first analysis in transplant medicine using a mixed treatment comparison (MTC) analysis. METHODS: An established Markov model was updated comparing four currently used immunosuppressive regimens (TR) which reflect real life use in clinical transplant practice not necessarily restricted to an approved label: "Sirolimus ϩ early withdrawal of Ciclosporin ϩ Steroids" (TR1), "Sirolimus-early-transition" (TR2), "Everolimus-early-transition" (TR3) and "Tacrolimus low dose ϩ Mycophenolate mofetil ϩ Steroids" (TR4). Patients could experience nine different states of post-transplant adverse events, discontinue TR or die. Transition probabilities were based on a MTC analysis for a 12 month time horizon. Costs and benefits were modeled from the perspective of the German statutory health insurance (SHI). Robustness of the model was tested in extensive sensitivity analyses. RESULTS: "Sirolimus early transition" (TR2) yields the highest life years (LY) (0.987 LY), while generating costs of 17,500 Euro for 12 months, slightly more than TR4 (conservative assumption). TR2 clearly dominates TR 3, a regimen with the second mTOR-inhibitor in market, and TR1, the regimen used in the European registration study, in terms of ICER (incremental cost-effectiveness ratio) in Euro per LY gained for 12 months. Incremental costs of 1,096 Euro for TR2 in comparison to TR4 resulted in an ICER of 548,000 Euro per QALY gained. CONCLUSIONS: The early transition to Sirolimus yields favorable results compared to the majority of other regimens investigated in terms of patient survival and ICER per life year gained. The analysis corroborates the feasibility of a MTC approach and reflects crucial outcomes which may support informed clinical decision making.
PUK12
COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY: A MODEL UPDATE
PUK13
COST-EFFECTIVENESS OF KETOSTERIL TREATMENT IN DIALYSIS PATIENTS
Tóth E 1 , Nagy B 2 1 Healthware Consulting Ltd., Budapest, Hungary, 2 Healthware Ltd, Budapest, Hungary OBJECTIVES: There are evidences on the favorable nutritional effects of Ketosteril in dialysis. Better quality of life and overall survival is attainable through improved nutritional status, which is also proved in practice. Our aim was to evaluate the cost-effectiveness of Ketodiet in dialysis in comparison with CKD treatment without Ketosteril. A cohort calculation was presented on the basis of representative patient attendance data from the Hungarian National Health Insurance Fund Administration (HNHIFA). Main outcome of the analysis was incremental cost of life years gained (LYG). METHODS: HNHIFA database uniquely contains detailed provision data from the whole Hungarian population of 10 million. All financed health care providers use the same report structure and reported data are strictly validated. Our retrospective analyses included data of 2004-2009 for all dialysed patients with chronic kidney disease (ICD code N17-19) as main diagnosis. Altogether 13 615 patients' data were included with a mean follow up of 53 months. Ctree• function of party package in R statistical program was used to determine empirical survival curves for patients treated with and without Ketosteril. Total costs of health care services (in-and outpatient care, labs, diagnostics, drugs, medical aids and sick leave) were taken into consideration. In case of death life years' loss were calculated on the basis of Hungarian life expectancy. Costs and outcomes were discounted with official Hungarian rate of 5%. RESULTS: The average total cost per patient was 9 596 € higher for Ketosteril arm (39 883 € vs 30 287 €). On the basis of mortality data we determined lost life years, which showed 0,97 years favour to Ketosteril (7,24 years vs 8,21 years). ICER of 3 509 460 HUF/LYG represents costeffectiveness of Ketosteril compared to other reimbursed health technologies in Hungary. CONCLUSIONS: Ketosteril therapy of dialysis patients could be a costeffectiveness treatment choice based on real world data analysis of Hungarian patients.
PUK14
COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
Xie J 1 , Zhou ZY 2 , Bui CN 3 , Yan Y 1 , De G 1 , Runken MC 4 , Wu EQ 2 1 Analysis Group, Inc., New York, NY, USA, 2 Analysis Group, Inc., Boston, MA, USA, 3 Astellas Pharma US, Inc., Northbrook, IL, USA, 4 Astellas Pharma US, Inc., Glenview, IL, USA OBJECTIVES: To assess the cost-effectiveness associated with mirabegron versus tolterodine extended release (ER) for treating overactive bladder (OAB) from a third party payer perspective in the US. METHODS: A Markov model was developed to follow a cohort of OAB patients treated with mirabegron versus tolterodine ER for a one-year period. Three health states were defined -normal: number of incontinence (I)ϭ0 and number of micturitions (M)Ͻ8; mild-to-moderate: 0ϽIՅ6 and MϽ16, or Iϭ0 and 8Յ MϽ16; severe: IϾ6 and MՆ16. Evidence from a 12-week clinical trial, comparing mirabegron 50 mg to tolterodine ER 4 mg, was used to estimate the initial health state distribution, transition probabilities, and discontinuation rates. Only direct costs were considered, including drug costs (2012 USD) and costs for OAB complications (2011 USD), with inputs from ReadyPrice ® and published literature. Effectiveness was defined as the proportion of patients in normal state. Results were expressed as the incremental cost per patient in normal state at the end of one-year. A subgroup analysis was conducted for patients who discontinued prior antimuscarinic therapy due to insufficient efficacy at baseline. Univariate and probabilistic sensitivity analyses were performed. RESULTS: For a one-year horizon, the incremental cost per patient in normal state associated with mirabegron vs. tolterodine ER was $5,580 (total cost of $4,707 and $4,420 and effectiveness of 17.72% and 12.57% for mirabegron and tolterodine ER respectively) for the total population. For the subgroup, the incremental cost per patient in normal state was $2,734 (total cost of $4,664 and $4,451 and effectiveness of 12.76% and 4.96% for mirabegron and tolterodine ER respectively). Results were robust to the model assumptions and inputs, while drug cost was the main driver of the model. CONCLUSIONS: Mirabegron is expected to be a cost-effective option compared to tolterodine ER, particularly in patients who discontinued prior antimuscarinic therapy due to insufficient efficacy.
PUK15 SEVELAMER IN EARLY STAGES NONDIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) DOMINATES CALCIUM CARBONATE THROUGH REDUCTION OF DEATHS AND HOSPITALIZATIONS
Ruggeri M 1 , Di Iorio B 2 1 Università Cattolica del Sacro Cuore, rome, Italy, 2 Ospedale Landolfi, Avellino, Italy OBJECTIVES: The INDEPENDENT study showed for the first time a significant reduction in mortality associated with Sevelamer, a phosphate binder, compared to Calcium Carbonate, in stage 3-4 nondialysis-dependent CKD patients. We evaluated the impact on CKD related hospitalizations in order to assess the cost-effectiveness profile from the NHS perspective. METHODS: The INDEPENDENT study involved 107 (Sev) and 105 (CaC) patients with a 36 months follow-up. Since few of them started dialysis, we also performed a subgroup secondary analysis on patients remaining dialysis free (76 vs 63). Individual hospitalizations in Nephrology, Cardiology and ICU were recorded as well the overall length of stay over the observation period. Correlated consumption of drugs, such as alpha and beta blockers, ARBs, ACE inhibitors, calcium channels blockers and erythropoietin, was also assessed. For hospitalizations and drugs, DGR tariffs and hospital acquisition cost respectively were used. As effectiveness end-point we considered the number of averted deaths. RESULTS: Calcium-treated patients were associated with greater frequencies of admission in all departments, thus generating significantly higher costs. The average savings generated by reduced hospitalizations far exceeded the acquisition cost of Sevelamer. In case of hospitalization, Sevelamer-treated patients showed a substantial reduction in the overall length of stay (-5.9 days, pϭ0.012). Such difference was also present in the secondary subgroup (-5.5 days, pϭ0.13). After 1000 bootstrap sampling, the primary analysis provided a mean cost difference of -€2282 ϩ/Ϫ €27 (CI 95%) and mean effectiveness difference of 0.09 ϩ/Ϫ 0.006 averted deaths in favor of Sevelamer. Similar figures were present in the secondary subgroup analysis (-€2403 ϩ/Ϫ €28 and 0.15 ϩ/Ϫ 0.007). Sevelamer A457
